MTOR and osteosarcoma: The lack of rapamycin activity in this system correlates with literature demonstrating that mTOR inhibitors combined with other agents have had limited clinical efficacy in osteosarcoma (Fleuren et al., 2014; Martin-Broto et al., 2017).